Polypyrimidine tract-binding protein (PTB) is an RNAbinding protein with multiple functions in the regulation of RNA processing and IRES-mediated translation. We report here overexpression of PTB in a majority of epithelial ovarian tumors revealed by immunoblotting and tissue microarray (TMA) staining. By western blotting, we found that PTB was overexpressed in 17 out of 19 ovarian tumor specimens compared to their matchednormal tissues. By TMA staining, we found PTB expression in 38 out of 44 ovarian cancer cases but only in two out of nine normal adjacent tissues. PTB is also overexpressed in SV40 large T-antigen immortalized ovarian epithelial cells compared to normal human ovarian epithelial cells. Using doxycycline-inducible small interfering RNA technology, we found that knockdown of PTB expression in the ovarian tumor cell line A2780 substantially impaired tumor cell proliferation, anchorage-independent growth and in vitro invasiveness. These results suggest that overexpression of PTB is an important component of the multistep process of tumorigenesis, and might be required for the development and maintenance of epithelial ovarian tumors. Moreover, because of its novel role in tumor cell growth and invasiveness, shown here for the first time, PTB may be a novel therapeutic target in the treatment of ovarian cancer.
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Introduction
Polypyrimidine tract-binding protein (PTB) is a member of the heterogeneous nuclear ribonucleoprotein family (also known as hnRNP I) with multiple functions. It was originally identified as a protein that bound to the pyrimidine-rich region within introns of pre-mRNA and was proposed as a splicing factor (Garcia-Blanco et al., 1989; Wang and Pederson, 1990) . It is now widely believed that PTB functions as a negative regulator of pre-mRNA splicing, blocking the inclusion of numerous alternative exons into mRNA (Black, 2003) , including its own exon . Besides roles in splicing, PTB has also been implicated in the regulation of other aspects of RNA metabolism, such as premRNA polyadenylation (Castelo-Branco et al., 2004) , mRNA stability (Kosinski et al., 2003; Knoch et al., 2004) , mRNA export from the nucleus (Zang et al., 2001) and mRNA localization in the cytoplasm (Cote et al., 1999) . In addition, PTB is involved in the control of cap-independent translation driven by the internal ribosomal entry site (IRES). PTB can bind the IRESs of viral and cellular mRNAs and either positively or negatively influence the IRES activity (Mitchell et al., 2001; Cornelis et al., 2005) .
PTB is widely expressed in many cells and tissues. It is mainly localized to the nucleus and distributed diffusely throughout the nucleoplasm with high concentration in a nuclear structure called the perinucleolar compartment (PNC) (Matera et al., 1995) , which is much more prevalent in tumor cells than in normal cells (Huang et al., 1997) . Recently, it has been reported that higher PNC prevalence significantly correlates with higher malignancy and poorer prognosis of breast cancer (Kamath et al., 2005) .
We have observed previously that human ovarian tumors overexpressed PTB and another splicing factor, SRp20, compared to matched-normal ovarian tissues. Correspondingly, we found more splice variants of the multidrug resistance-associated protein 1 (MRP1/ ABCC1) as well as CD44 in ovarian tumors than in matched-normal ovarian tissues (He et al., 2004) . It remains to be determined whether these two splicing factors directly participate in the splicing of the MRP1 and CD44 genes. Others found that overexpression of PTB in glioblastoma tissues coincided with the increased exclusion of the a-exon of fibroblast growth factor receptor 1 in transformed glial cells (Jin et al., 2000 (Jin et al., , 2003 . Nevertheless, it is unknown whether PTB plays any functional role in tumor progression.
In this report, we expanded our previous observation to more ovarian cancer specimens and confirmed the overexpression of PTB in ovarian tumors at the cellular level. We also show that knockdown of PTB expression by small interfering RNA (siRNA) substantially impairs ovarian tumor cell growth, colony formation and invasiveness in vitro.
Results
Immunohistochemical staining of tissue microarrays for PTB We confirmed our previous observation that PTB was overexpressed in human epithelial ovarian cancer (EOC) by western blotting of another 19 pairs of matched ovarian tumor and normal tissues and show overexpression of PTB in 17 pairs (Supplemetary Data Figure S1 ). To compare PTB expression at the cellular level between normal ovarian epithelia and ovarian tumors, we performed immunohistochemical staining for PTB on an ovarian tumor tissue microarray (TMA) that contained tissue spots of 48 cases of advanced EOC and 13 cases of normal adjacent ovarian tissues. After staining, 44 cancer cases and 11 normal cases were judged valid and analysed further. Our rule for valid cases was that there were a minimum of two satisfactory cores for cancer and one satisfactory core for normal ovary. Unsatisfactory cases were those with missing core(s), scant/insufficient tumor cells and increased background or folded/ wrinkled/torn sections. Overall, the stainings of three cores of a case were very similar, as exemplified in Figure 1a . Out of 44 valid cancer cases, 33 had score differences no greater than 1 both in intensity and in frequency among three cores, indicating that staining was reliable and unbiased.
The staining for PTB in the majority of ovarian tumor tissues was positive and strong, whereas in most normal ovarian tissues the staining was negative. Figure 1b shows examples of PTB staining in tumor and normal ovarian tissues. The results of the staining are summarized in Table 1 . We note that most normal tissues contained only stromal cells, and only one retained surface epithelium. In this case, we found that the staining of normal epithelium for PTB was negative, whereas staining for two other splicing factors, ASF/SF2 and U2AF65, was very strong (Figure 1b) . In contrast, the staining for all three splicing factors was very strong in tumors ( Figure 1b ). This result suggests that the overexpression of splicing factors in EOC compared to normal ovarian epithelium is not universal; indeed, overexpression of PTB in EOC appears to be unique in this disease. In support of this observation, we also stained 16 conventional normal ovarian tissue sections with some surface epithelia retained and 10 epithelial ovarian tumor tissue sections for PTB and confirmed the above observation, that is, the staining of normal ovarian surface epithelia was negative or very weak positive, whereas that of EOC was strong positive (data not shown).
Immortalization of ovarian epithelial cells increases the expression of PTB
The observation that normal ovarian tissues express low levels of PTB compared to ovarian tumors raised the question of when during oncogenesis this splicing factor becomes overexpressed. Hence, we examined by western blotting the expression of PTB in normal human ovarian surface epithelia (HOSE), life-extended HOSE (IOSE398) (Maines-Bandiera et al., 1992) , truly immortalized HOSE (IOSE120T) (Liu et al., 2004) and ovarian epithelial tumor cell lines PA-1, SKOV3, OVCAR8 and A2780. As shown in Figure 2a , the expression of PTB is substantially overexpressed in lifeextended IOSE398 cells and maintained at high levels in IOSE120T and ovarian tumor cell lines, compared to normal HOSE cells. Further, we compared the PTB levels at different passages of IOSE398 cells, which senesce at around passage 20. As can be seen in Figure 2b , PTB levels were gradually reduced when cells were approaching senescence. These results suggest that the upregulation of PTB is an early event in the neoplastic transformation of ovarian epithelial cells and might be required for cell growth. In support of this notion, we found by staining an ovarian disease-progression TMA that the expression levels of PTB are highest in invasive ovarian tumors, lowest in benign ovarian tumors and in between in borderline/low malignant potential ovarian tumors (data not shown).
Knockdown of PTB expression by vector-based siRNA Our above observation raised another question of whether overexpressed PTB plays any functional role(s) in maintaining ovarian tumor cell growth. To address this, we used siRNA technology to knockdown the expression of PTB in tumor cells and then examined the effects of such manipulations on cell growth and malignancy, the latter assessed in an in vitro invasiveness assay. To knockdown significantly PTB expression, we tested over 10 vector-based siRNAs targeting different regions of PTB mRNA and found three to be very effective in suppression of PTB expression. Moreover, the introduction of these three vector-based siRNAs into Michigan Cancer Foundation (MCF)-7 cells, a breast cancer cell line, also caused suppression of cell growth (see Supplementary Data, Figure S3 ). In this study, we chose two of them (PTB small hairpin RNAs 1 and 3 (shRNA1 and shRNA3)) and transferred them individually to a lentiviral vector (Wiznerowicz and Trono, 2003) as described in the Materials and methods. We then established sublines of the epithelial ovarian tumor cell line A2780 that express tetracycline-inducible PTB siRNA. The sublines (named as A2780/PTBsi1 and A2780/PTBsi3, respectively) carry both expression cassettes of tTR/KRAB-Red and PTB shRNA1 or PTB shRNA3 (Figure 3a) . In the presence of doxycycline (DOX), the fusion protein tTR/KRAB-Red is bound by DOX and dissociated from the tetO, thus unblocking the downstream PTB shRNA, allowing it to be expressed. The expression of PTB at mRNA and protein levels in the absence and presence of DOX is shown in Figure 3b . It can be seen that the expression of PTB is controlled by DOX: in the presence of DOX, PTB in ovarian cancer X He et al PTB expression is significantly knocked down at both mRNA and protein levels. In contrast, the expression of PTB in the control subline A2780/LV, which carries LV-tTR/KRAB-Red and the lentiviral vector without PTB shRNA, is not influenced by DOX. In addition, we showed that knockdown of PTB expression by DOXinduced siRNA was not accompanied by non-specific interferon response, a major concern in studies involving siRNAs (see Supplementary Data Figure S4 ).
Knockdown of PTB expression suppresses the growth of ovarian tumor cells in vitro Using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, we compared the proliferation of A2780/PTBsi1 and A2780/PTBsi3 in the presence and absence of DOX. As shown in Figure 4a , the growth of A2780/PTBsi1 and A2780/ PTBsi3 was suppressed substantially in the presence of DOX, whereas the control subline A2780/LV, as well as the parental A2780 cells grew similarly in both conditions (with and without DOX). It is worth noting that in the absence of DOX, there is no significant difference in cell growth among the four cell lines, indicating that the introduction of lentiviral vectors into the cell itself did not influence cell growth. We counted cell numbers at 24 h intervals, using a Coulter Counter (Beckman Coulter, Fullerton, CA, USA). The result was highly consistent with that obtained by MTT assay. It can be seen in Figure 4b that A2780/PTBsi1 and A2780/PTBsi3 grow substantially more slowly in the presence of DOX. By contrast, we observed no such difference in the control subline or parental A2780 cells. We also observed similar results in a breast cancer cell line, MCF-7, following knockdown of PTB (Supplementary Data Figure S3 ), indicating that growth suppression following PTB knockdown is likely a general phenomenon and not confined to one tumor histotype.
Knockdown of PTB expression decreases the invasiveness of ovarian tumor cells To determine whether overexpression of PTB makes any contribution to the invasiveness, and therefore, the malignancy of ovarian tumor cells, we examined two malignant properties, anchorage-independent growth (AIG) and invasiveness, in the A2780/PTBsi1 and A2780/PTBsi3 cells when their PTB expression was manipulated by DOX. The AIG of tumor cells was measured by the formation of colonies in soft agar. As shown in Figure 5a , the colonies formed when A2780/ PTBsi1 and A2780/PTBsi3 were grown with DOX were only 10.473.1 and 19.574.4%, respectively, of that formed when grown without DOX, indicating that knockdown of PTB expression substantially impaired the AIG of A2780 cells. By contrast, both the control subline and the parental A2780 cells exhibited little differences in their ability to form colonies in soft agar when grown with DOX and without DOX (the percentages were 90.172.9 and 87.472.3%, respectively). The invasiveness of tumor cells was measured by their abilities to degrade the basement membrane matrix proteins in the coating layer, which serves as a barrier to discriminate invasive cells from non-invasive cells, and ultimately pass through the pores of a polycarbonate membrane. As shown in Figure 5b , when A2780/PTBsi1 and A2780/PTBsi3 cells were grown with DOX, the number of invasive cells (indicated by arrows in the figure) was far less (23.5714.1 and 14.073.3%, respectively) than when they were grown without DOX, indicating that knockdown of PTB expression also greatly reduced the invasive potential of A2780 cells. In contrast, DOX treatment produced little or no effect on the invasive abilities of the control cell lines A2780/LV and A2780 (the percentages were 103.3711 and 81.678.0%, respectively).
Discussion
In this study, we confirmed our previous observation that PTB was overexpressed in human EOC by immunohistochemical staining of EOC TMA. Moreover, we found that PTB expression was upregulated in immortalized ovarian epithelial cells as well as in ovarian tumor cell lines, compared to normal or untransformed ovarian epithelial cells, a novel observation. Additionally, we demonstrated that knockdown of PTB expression by siRNA impaired the growth of ovarian tumor cells and diminished their malignant potential. Together, these results suggest to us that overexpression of PTB could be an important component of a multistep process of tumorigenesis and might be required for the development and maintenance of EOC. 
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The mechanism that leads to the upregulation of PTB expression in ovarian tumors remains to be elucidated. Given that PTB expression is increased in SV40 large T antigen (TAg)-transduced OSE cells (see Figure 2) and TAg disrupts the normal actions of tumor suppressor pRb and p53 (Bryan and Reddel, 1994) , it is possible that the expression of PTB is under control of these two proteins. However, as PTB is overexpressed in PA-1, which expresses wild-type p53 as well as in SKOV3 that does not express p53 at all (Jin et al., 2002) , p53 probably plays no role in PTB overexpression. Clearly, other pathways cannot be excluded because TAg also interacts with proteins other than pRb and p53 (Kasper et al., 2005) .
As indicated in the Introduction, PTB is a key regulator of alternative splicing, and is involved in the repression of inclusion of many alternative exons (Wagner and Garcia-Blanco, 2001 ). Therefore, overexpression of PTB is very likely to cause alterations in splicing patterns that may have such effects as we have shown herein, and we are presently examining this in our system. Defects in pre-mRNA splicing have been shown to be causes of a variety of human diseases (Faustino and Cooper, 2003) . Mounting evidence suggests that altered splicing is associated with and possibly involved in tumor progression and/or metastasis (Venables, 2004) . Recent computational analyses, based on alignments of expressed sequence tags to human RefSeq mRNAs or human genomic DNA, revealed that many alternatively spliced variants were significantly associated with cancer, and the majority of these genes have functions related to cancer (Wang et al., 2003; Xu and Lee, 2003) . In general, the direct causes behind the alteration of pre-mRNA splicing can be divided into two categories: mutations in cis-elements and changes in trans-acting factors. At present, it is not clear whether mutations make significant contributions to aberrant splicing found in tumors. Our finding of overexpresssion of PTB in ovarian tumors indicates that aberrant splicing is at least partially because of changes in trans-acting splicing factors. As pre-mRNA splicing is a complex cellular process involving many other splicing PTB in ovarian cancer X He et al factors, to have a better understanding of why and how splicing patterns change in tumor cells, it is necessary to have a global view of expression of all splicing factors in tumor and normal cells, and some of our current effort is directed to addressing this matter.
Overexpression of PTB in the majority of ovarian tumors raises possibilities that PTB could be a useful biomarker for the diagnosis and/or prognosis of ovarian cancer, or even as a novel therapeutic target. Ovarian cancer is the deadliest disease among all gynecological cancers (Jemal et al., 2003) . Two facts account for this dismal outcome: one is the absence of reliable early detection markers; and the other is inadequacy of present therapy for advanced disease (Ozols et al., 2004) . Therefore, to improve patient survival, it is critical to identify new biomarkers for early detection. Given the current absence of any preventable etiologic factors and effective tools for screening, another way to approach improving patient survival is to discover biomarkers that can lead to a better management of patients after initial diagnosis (Bast et al., 2005) . To establish the usefulness of PTB as a biomarker, more work is needed to determine whether there is a correlation among the expression of PTB and subtype, PTB in ovarian cancer X He et al grade and stage of ovarian cancer, as well as clinical outcomes such as therapy response, survival, progression-free survival etc. These studies are presently underway in our laboratories and will be reported elsewhere.
The results that knockdown of PTB expression causes suppression of tumor cell proliferation, suppression of AIG and suppression of invasiveness strongly support the notion that PTB is important in maintaining ovarian tumor cell growth and malignant potential. To our best knowledge, ours is the first report to show such effects. At present, it is not clear what mechanisms mediate these effects. Given the multiple functions of PTB, these effects could be related to changes in alternative splicing, mRNA stability or IRES-driven translation of certain genes. However, current knowledge about the targets of PTB cannot entirely explain our observations. Therefore, it is very likely that there exist some unidentified substrates of PTB that are involved in the maintenance of ovarian tumor cell growth and malignancy by PTB. Despite these gaps in our knowledge, our results support the idea that PTB might have potential as a therapeutic target for the treatment of ovarian cancer, and our laboratories are pursuing these lines of investigation. In addition, we recently performed a microarray analysis comparing controls to cells with PTB knocked down by siRNA. Our preliminary results, to be detailed elsewhere, have revealed that a number of genes associated with tumor growth and metastasis are downregulated and a number of genes associated with tumor suppression are upregulated in PTB-knockdown A2780 cells, supporting the observations of this study.
Finally, a very recent report showed that knockdown of PTB in MCF-7 cells inhibited apoptosis triggered by TRAIL and ectopical expression of PTB in MCF-7 cells caused a small increase in apoptosis (Bushell et al., 2006) . These results are somewhat in contrast to what we present here. However, the report did not show whether knockdown of PTB itself affected cell growth. Also it is worth noting that MCF-7 cells already overexpress PTB compared to normal human mammary epithelial cells (HMEC) or non-tumorigenic immortalized HMEC (our unpublished data). Further overexpressing PTB ectopically in MCF-7 cells might cause some artificial phenomena.
Materials and methods
Cell lines and cell culture conditions These are detailed in the Supplementary Data.
TMA of EOC
TMA slides were obtained from the Gynecologic Oncology Group (GOG) Tissue Bank in Columbus, (OH, USA). The TMA contained 165 randomly distributed 1 mm cores with 150 cancers and 15 adjacent normal ovaries. Among the cancers, there were 48 cases of advanced stage EOC (25 stage III and 23 stage IV) and one case of uterine adenocarcinoma with up to three cores for each case (except one case with six cores). Cores of adjacent normal ovarian tissue were from 13 patients with ovarian cancer. Of these, 11 cases had one core for each and two cases had two cores for each.
Western blotting
Western blotting was performed as described previously (He et al., 2004) . The densities of protein bands were measured using software Scion Image (Scion Corporation, Frederick, MD, USA).
Immunohistochemical staining of TMA The procedure of immunohistochemical staining and its evaluation are described in detail in the Supplementary Data.
Preparation of lentiviruses carrying tetracycline-inducible expression cassette of shRNA The DNA fragments coding for PTB shRNA1 and 3 were generated by annealing of two pairs of complementary oligonucleotides. The procedures for cloning of the DNA fragment into the lentiviral vector and for preparation of lentiviruses are detailed in the Supplementary Data.
Establishment of stable cell lines expressing tetracyclineinducible PTB siRNA We first established cell lines transduced by lentiviruses LVtTR/KRAB-Red, and then re-infected them with lentiviruses LV-THsiPTB. Clones expressing both red fluorescent protein and green fluorescent protein were selected and expanded. The regulation by DOX of siRNA expression in these clones was verified by measuring PTB expression by both reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting.
Cell proliferation assay
Cell proliferation was determined using MTT assay. Cell growth curves were obtained by counting cells grown in 24-well plates using a Coulter Counter (Beckman Coulter). Detailed procedures for these experiments are described in the Supplementary Data.
Soft agar colony formation
The assay was performed in 60 mm dishes or six-well plates that contained two layers of soft agar. The top and bottom layers were 0.3 and 0.4% agarose, respectively, in Dulbecco's modified Eagle's medium with 5% fetal bovine serum. Five thousand cells together with or without DOX were added to the top agarose before pouring. Colonies were counted manually after 2-3 weeks incubation at 371C, 5% CO 2 .
In vitro invasiveness assay The invasive properties of tumor cells were analysed using CytoSelect Cell Invasion Assay kit (Cell Biolabs, Inc., San Diego, CA, USA), according to the manufacturer's instructions. The procedure is described in detail in the Supplementary Data.
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